Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

A news brief in the Aug. 31, 2009, issue, "AdvoCare loses verdict to distributors," should have included a comment from an AdvoCare spokeswoman saying the company believes the Badgetts, its former distributors, were terminated appropriately and AdvoCare intends to appeal the jury verdict that went against the firm. "The Tan Sheet" regrets the omission and corrected the brief posted on our Web site (1"The Tan Sheet" Aug. 31, 2009, In Brief)

You may also be interested in...

AdvoCare loses verdict to distributors

The Carollton, Texas-based multi-level marketer of nutritional and skin-care products must pay $1.9 million to former distributors under a Dallas County court jury verdict finding AdvoCare violated Texas deceptive trade practices law. Dallas law firm Kilgore & Kilgore, counsel for plaintiffs Bruce and Teresa Badgett, said Aug. 26 that AdvoCare refused to change its marketing and business structures to "meet the accountability demands of" the Badgetts and then cancelled their distribution agreements. A spokeswoman said the Badgetts were terminated appropriately and AdvoCare intends to appeal the decision. Separately, the firm and competitive swimmer Jessica Hardy filed suit against each other after Hardy failed a performance-enhancing drug test and blamed an AdvoCare supplement (1"The Tan Sheet" Feb. 23, 2009)

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts